At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Drug Response Predictor® (DRP) (device)
- How long the study runs
- Study runs about 104 months (dates as stated)
- About the drug or intervention
- Drug Response Predictor® (DRP) — device: A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
- Patient visit burden
- Not specified by the sponsor
In plain English
This is a screening list for a clinical trial looking at ovarian cancer, run by a company called Allarity Therapeutics. It is for people with a type of ovarian cancer called epithelial ovarian cancer that has come back or got worse despite treatment. The trial team uses this list to see who might be able to join.
Who can take part
- You have epithelial ovarian cancer confirmed by looking at tissue under a microscope.
- Your cancer got worse within 6 months of finishing platinum-based chemotherapy, or you cannot have platinum treatment for another reason.
- You have had no more than one previous course of treatment after your cancer stopped responding to platinum chemotherapy (or if you could not have platinum at all).
- A sample of your tumour tissue, stored in wax (called FFPE tissue), is available for testing.
Who may not be able to
- Your cancer got worse while you were still having platinum-based chemotherapy (doctors call this platinum-refractory disease).
- You have had another type of cancer, unless it was stage I or II and the study doctor believes it has been cured.
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team about visits, how long the trial lasts, and what taking part would involve.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- Female
- Number of participants
- 60
- Started
- 2019-04-11
- Last checked
- 2026-07
Plain English Summary
What is this study?
- • Testing a new treatment for ovarian cancer
- • Clinical study - 60 participants
- • The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with ovarian cancer
- • Female only
Where?
- • Glasgow - Beatson West of Scotland Cancer Centre
- • London - Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: Female only
Treatment history
Treatments you must have had:
- ✓ of therapy in the platinum resistant
What the study is looking for
- ✓Patients with histological confirmed epithelia ovarian cancer
- ✓Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of...
- ✓Patients have received no more than one previous treatments in the platinum resistant or platinum ineligible setting
- ✓FFPE tumor tissue available
Who cannot take part
- ✗Patients who have platinum-refractory disease, defined as progression during the last platinum-based drug treatment.
- ✗Other cancer with exception of any stage I and II cancer that is deemed cured by the Investigator
See the full criteria
Where Is This Study? (2 UK sites)
Beatson West of Scotland Cancer Centre
Glasgow G12 0YN, United Kingdom
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital
London, United Kingdom
How to Get in Touch
US: Kathleen Moore
Sponsor contactCONTACT
Europe: Rebecca Kristeleit
Sponsor contactCONTACT